Targeted Therapy for Metastatic Renal Carcinoma: an Update

Rodrigo Donalisio da Silva1, Diedra Gustafson1, Leticia Nogueira1, Priya N. Werahera2, Wilson R. Molina1,3, Fernando J. Kim1,3

1Department of Urology, Denver Health Medical Center, Denver, Colorado, USA; 2Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; 3University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA

Abstract

Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the treatment of advanced renal cell carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of relevant studies published in PubMed between 2000 and 2014 were analyzed by two authors. Abstracts were selected if they were published in English, data reported was of phase II or III clinical trials, and outcomes followed FDA approval. If consensus between the two authors was achieved, they were included in the review. Key words used were “target therapy” and “metastatic renal cell carcinoma”. The results of the studies analyzed in this review support the benefits of targeted therapy in metastatic RCC. These include improved progression-free survival, overall survival, and quality of life as well as reduced toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC makes these drugs a preferred option as a primary treatment for these patients. Copyright: The Authors.

Received: 15 October 2014; Accepted after revision: 20 October 2014; Published: 21 October 2014

Author for correspondence: Professor Fernando J. Kim, MD, FACS, Department of Urology, Denver Health Medical Center, Denver, Colorado, USA. E-mail: fernando.kim@dhha.org


Introduction

Renal cell carcinoma (RCC) represents 2-3% of all cancers, with highest incidence occurring in the Western countries (1, 2). In the last two decades, its incidence has been steadily increasing (1). Although a higher incidence of small renal masses are being detected, approximately one third of the patients still have metastatic disease at diagnosis (3, 4). Only a small subset of patients have chosen the historical use of immunotherapy including interleukin-2 (IL-2) and interferon alpha (IFN-α) in the treatment of advanced RCC. These patients have a 5-year survival rate of 6% (5, 6). The moderate efficacy of immunotherapy was also confirmed by a Cochrane meta-analysis using 42 studies (7). Recently, new drugs have emerged in the arsenal of systemic therapy for advanced
A better understanding of the molecular signaling that governs tumor growth and progression has led to the development of molecular therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, resulting in significant improvement in overall survival and quality of life (3). The objective of this systematic review is to briefly describe the latest data regarding targeted therapies used in the treatment of advanced renal cell carcinoma.

Methods

Search Strategy and Study Selection

Search strategy and study selection were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Abstracts of relevant studies and clinical trials from PUBMED/MEDLINE (2000 to 2014) were analyzed by two authors and were included if both agreed with the selection. A third author was consulted when the two authors disagreed. After abstract selection, all manuscripts were revised and were only included if it met the selection criteria and if consensus was achieved by the authors.

The key words used were “target therapy” and “metastatic renal cell carcinoma”. The terms identified included names of following therapies: Sunitinib, Sorafenib, Pazopanib, Axitinib, Cediranib, Everolimus, Temsirolimus, Bevacizumab, and Erlotinib.

Study inclusion criteria included contemporary articles published in English after 2000 that reported data of phase II and III Clinical Trials and outcomes followed FDA approval. A total of 40 studies were eligible for review.

Data Extraction and Analysis

Variables collected from eligible studies were: study name, period of the study, molecular targets of the drug, FDA approval status, indication of treatment, recommended dosage of the drug, and safety and efficacy of the drug. Efficacy was evaluated by the Overall survival (OS), progression free survival (PFS), and time to progression (TTP) as defined by the FDA Center for Drug Evaluation and Research. Safety was evaluated by the severity of adverse events defined by the Common Toxicity Criteria (CTC).

Evidence synthesis

VEGF Targeted Therapies

Angiogenesis is critical for tumor growth and progression, especially in solid tumors with vast vascularization such as RCC. Vascular endothelial growth factor and its receptor (VEGF/VEGFR) mediate VEGFR regulation of vessel permeability, endothelial cell activation, survival, proliferation, invasion, and migration. VEGFR and PDGFR pathways exhibit tyrosine kinase activity and activate downstream signaling pathways as the Raf/MEK/ERK (8). During angiogenesis, Raf is key in regulating endothelial cell survival by controlling apoptosis pathways (9). Several drugs have been developed to target this pathway and control tumor angiogenesis. A list of novel therapeutics targeting the angiogenesis/VEGF pathway is summarized in Table 1.

Sorafenib

Sorafenib is an oral multi-tyrosine kinase inhibitor with activity against Raf-1 serine/threonine kinase, B-Raf, vascular endothelial grow factor receptor 2 (VGEFR-2), PDGFR, and c-kit. A phase III trial (TARGET trial) showed a significantly longer PFS with sorafenib compared to placebo (5.5 vs. 2.8 months; p < 0.001). Moreover, partial responses were significantly higher (10%) in those patients treated with sorafenib compared to 2% of those treated with placebo (P<0.001). Cross over was performed in patients of the placebo group which presented a reduced risk of death. 16 months after crossover, the overall survival in the sorafenib treated cohort was 17.8 months compared to 15.2 months for the patients initially treated with placebo (p < 0.146). The estimated overall survival for the placebo-treated patients was 14.3 months.

Sorafenib is considered a second line therapy and the suggested dose is 800 mg a day. Adverse effects were skin rash, hand-foot skin reaction, and fatigue. Discontinuation of the treatment was
required in 9% of patients, and no deaths were reported due to toxicity of the treatment (10). Sorafenib was the first anti-angiogenic multi-tyrosine kinase inhibitor for mRCC approved by the FDA (2005).

### Sunitinib

Sunitinib is also an inhibitor of VEGFR1-3, c-kit, FLT-3 and PDGFR. Sunitinib has direct antitumor and anti-angiogenic activity (10, 11). This drug was approved by the FDA in 2006 and is now considered a first-line therapy for mRCC. It is orally administered with the recommended daily dose of 50 mg/day by a schedule 4/2.

In a phase III trial comparing sunitinib to interferon, the sunitinib arm showed doubled progression-free survival (PFS), improving PFS from 5 months with interferon to 11 with sunitinib as monotherapy. The objective response rates were 47% and 12% for sunitinib and interferon-α, respectively (P < 0.001) and the median overall survival was 26.4 months for sunitinib and 21.8 months for interferon-α (P = 0.051) (12). Moreover, access expanded globally, and another phase III trial was designed to provide sunitinib on relatively unselected or trial-ineligible patients with brain metastases and poor ECOG performance status. Treatment with sunitinib demonstrated a PFS of 10.9 months and median overall survival of 18.4 months with similar overall survival in patients with and without prior cytokine therapy. Sunitinib did not present high severity adverse events, but hypertension, fatigue, diarrhea, and hand-foot syndrome were described during treatment with this drug. Sunitinib was compared with IFN-α regarding quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST score). Sunitinib resulted in better clinical efficacy and quality-of-life outcomes compared with IFN-α for mRCC patients (13).

### Pazopanib

Pazopanib is a second generation, orally administered multi-target tyrosine kinase receptor inhibitor that blocks VEGFR1-3, RET, and c-kit receptors (11-13). A
Table 1: Angiogenesis/VEGF inhibitors: dose, molecular target and PFS outcome

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Target</th>
<th>Line of Therapy</th>
<th>Study</th>
<th>PFS (months)</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib</td>
<td>Oral; 400mg BID</td>
<td>Raf-1 serine/threonine kinase, B-Raf, VEGFR-2, PDGFR, C_KIT</td>
<td>Second Line</td>
<td>Sorafenib v. Placebo</td>
<td>5.5 v. 2.8*</td>
<td>(10)</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Oral; 50mg qd</td>
<td>VEGFR1-3, c-KIT, FLT3, PDGFR</td>
<td>First Line</td>
<td>Sunitinib v. IFN</td>
<td>11 v. 5*</td>
<td>(11)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Oral; 800mg qd</td>
<td>VEGFR1-3, RET, c-kit</td>
<td>First Line</td>
<td>Pazopanib v. Sunitinib</td>
<td>8.4 v. 9.5</td>
<td>(15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>First Line</td>
<td>11.1 v. 2.8*</td>
<td>(14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Second Line</td>
<td>7.4 v. 4.2*</td>
<td>(17)</td>
</tr>
<tr>
<td>Axitinib</td>
<td>Oral; 5mg tid</td>
<td>VEGFR1</td>
<td>First Line</td>
<td>Axitinib v. Sorafenib</td>
<td>10.1 v. 6.5*</td>
<td>(19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Second Line</td>
<td>6.7 v. 4.7*</td>
<td>(18)</td>
</tr>
<tr>
<td>Cediranib</td>
<td>Oral; 45mg tid</td>
<td>VEGF1</td>
<td>First Line</td>
<td>Cediranib v. Placebo</td>
<td>12.1 v. 2.8*</td>
<td>(22)</td>
</tr>
<tr>
<td>Bevacizumab-IFN</td>
<td>IV; 10mg/Kg 2/2weeks</td>
<td>VEGF</td>
<td>First Line</td>
<td>Bevacizumab-IFN v IFN</td>
<td>8.5 v. 5.2*</td>
<td>(26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bevacizumab-IFN v IFN</td>
<td>10.2 v. 5.4*</td>
<td>(25)</td>
</tr>
<tr>
<td>Bevacizumab-Erlotinib</td>
<td>Oral; 150mg qd</td>
<td>EGFR tyrosine kinase</td>
<td>First Line</td>
<td>Bevacizumab-Erlotinib v Bevacizumab</td>
<td>9.9 v. 8.5</td>
<td>(28)</td>
</tr>
</tbody>
</table>

PFS, progression free survival; i, investigational drug; cyto, post-cytokine; vegf, post-VEGF; mtor, post-mTORi; * statistically significant.

randomized phase III trial comparing pazopanib with placebo showed a significant improvement in PFS and tumor response in treatment-naïve metastatic RCC patients (54%) and previously cytokine-treated patients (46%). Compared to placebo, the overall PFS was 9.2 months for the pazopanib group vs 4.2 months for placebo patients (HR: 0.46; 95% CI: 0.34-0.62; p<0.0001). In the treatment-naïve subpopulation, PFS was 11.1 months vs 2.8 months (HR: 0.40; 95% CI: 0.27-0.60; p<0.0001) for pazopanib and placebo, respectively. In patients pretreated with cytokine, PFS was 7.4 months vs 4.2 months (HR: 0.54; 95% CI: 0.35-0.84; p<0.001) for pazopanib and placebo, respectively (14).

Another non-inferiority randomized phase III trial compared pazopanib with sunitinib. PFS and OS of pazopanib were not inferior to sunitinib, and quality of life with pazopanib was statistically better than sunitinib in those patients (15). Pazopanib demonstrated acceptable safety and tolerability even though it has been associated with liver toxicity. Common adverse events reported with pazopanib were hair color changes, nausea, anorexia, and vomiting while Grade 3-4 toxicity effects were hypertension, diarrhea, and liver toxicity (14). Pazopanib was approved by the FDA in 2009. It is considered as a first-line treatment and an option as a second-line treatment in previously cytokine-treated patients (16, 17).
Table 2: m-TOR inhibitors: dose, molecular target and PFS outcome

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Target</th>
<th>Line of Therapy</th>
<th>Study</th>
<th>PFS (months)</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temsirolimus</td>
<td>IV; 25mg weekly</td>
<td>mTOR; HIF1-2; VEGF</td>
<td>First Line</td>
<td>Temsirolimus v IFN</td>
<td>10.9 v. 7.3*</td>
<td>(38)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temsirolimus v Sorafenib</td>
<td>4.3 v. 3.9</td>
<td>(45)</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Oral; 10mg Qd</td>
<td>mTOR; HIF1; VEGF</td>
<td>Second/Third Line</td>
<td>Everolimus v Placebo</td>
<td>4.9 v. 1.9*</td>
<td>(36)</td>
</tr>
</tbody>
</table>

PFS, progression free survival; vegf, post-VEGF; * statistically significant.

Pazopanib is usually administered orally at 800 mg daily.

**Axitinib**

Axitinib is another second-generation inhibitor of VEGFR-1 which also has minimal effect on other targets. Axitinib is a second-line therapy option in cytokine-refractory metastatic RCC. A Phase III clinical trial (18) that compared axitinib and sorafenib in 723 patients who were previously treated unsuccessfully with cytokine or VEGF inhibitors showed a median PFS of 6.7 months for the axitinib group and 4.7 months for the sorafenib group (p<0.0001). The OS was 29.9 months with a TTP of 15.7 months.

The overall response rate was 22.6%, and the median duration of response was 17.5 months. The adverse events of axitinib included diarrhea, hypertension, fatigue, dysphonia, and hand-foot syndrome (19). Grade 3 to 4 adverse events included hand-foot syndrome, fatigue, hypertension, dyspnea, diarrhea, dehydration, and hypotension. Axitinib was approved by the FDA in 2012. Its potency is 50 to 450 times greater than the first-generation VEGFR inhibitors (20, 21). The recommended dose of axitinib is 5.0 mg twice a day (18).

**Bevacizumab**

Bevacizumab is a humanized recombinant IgG monoclonal antibody that binds to VEGF-A, increasing vascular permeability and reducing proliferation and migration of endothelial cells. The AVOREN (phase III) double-blind trial randomized 649 naïve patients to receive bevacizumab (10 mg/kg every 2 weeks) plus IFN-α (9 MU) or placebo and IFN-α. The median overall response (OR) and stable disease in the bevacizumab plus IFN-α versus placebo plus IFN-α arms were 31 and 46% versus 13 and 50%, respectively. PFS was significantly longer in the bevacizumab and IFN-α (10.2 versus 5.4 months; p<0.0001), but only in good-risk and intermediate-risk patients. In poor-risk patients, bevacizumab did not present any benefits (24).

After progression, crossover was performed and the median OS was 23.3 months for bevacizumab-IFN-α vs 21.3 months for IFN-α alone (p=0.336) (25). Fatigue,
asthenia, and proteinuria were the most common grade 3 toxicities (11, 26). FDA approved bevacizumab in 2009 at 10 mg/kg IV every 2 weeks in combination with IFN-α. Another phase III (CALGB 90206) (26) randomized trial enrolled 732 previously untreated metastatic RCC patients for bevacizumab (10 mg/kg each 2 weeks) plus IFN-α (9 million U/3 times weekly) versus IFN-α monotherapy. PFS was 8.5 months for the combination compared to 5.2 months for INF-α alone. After crossover, median OS was 18.3 for the combination compared to 17.4 for IFN-α alone. OR with bevacizumab plus IFN-α was higher compared to IFN monotherapy (25.5 vs 13.1% p < 0.0001). The combination therapy was associated with higher grade 3 to 4 hypertension (HTN), anorexia, fatigue, and proteinuria.

Erlotinib

Erlotinib inhibits the tyrosine kinase domain of epidermal growth factor receptor (EGFR), leading to the inhibition of EGFR auto-phosphorylation and downstream signaling (27). Erlotinib demonstrated encouraging activity in renal cell carcinoma when associated with bevacizumab in a phase II trial (28). 63 patients with metastatic clear-cell RCC were treated with bevacizumab at 10 mg/kg every 2 weeks and erlotinib at 150 mg/daily. Objective responses were achieved in 25% of the patients, disease was stable in 61% after 8 weeks, and survival at 18 months was 60%. Another randomized double-blind phase II trial compared the combination of erlotinib and bevacizumab with bevacizumab alone. Combined therapy did not provide additional benefits when compared to bevacizumab alone (29).

The combination of erlotinib with sirolimus in metastatic RCC did not show benefits when compared to a single agent in a phase II trial (30). 25 patients previously treated with sunitinib and/or sorafenib were evaluated and included. Partial responses or complete responses were observed; however, stable disease was noted in 21.8% of patients in 46 months. The progression-free survival and overall survival were 12 and 40 weeks respectively. Currently, Erlotinib is not approved by the FDA for the treatment of metastatic RCC.

Mammalian Target of Rapamycin (mTOR) Inhibitors

Another signaling pathway that is critical for cellular growth, proliferation, and angiogenesis is the mammalian target of rapamycin (mTOR) pathway (31). This pathway is more significantly mutated in clear-cell RCC, high-grade tumors, and tumors with poor prognostic features (32, 33). A list of novel therapeutics targeting the mTOR pathway is summarized in Table 2.

Everolimus

Everolimus is an mTOR inhibitor used in the treatment of VEGF-refractory disease. A phase II trial was conducted using everolimus at a daily dose of 10 mg for a 28-day cycle in 41 patients with metastatic RCC who were previously treated with one therapy at most. Median progression-free survival of 11.2 months and median overall survival of 22.1 months was reported (34). Partial responses were observed in 5 patients, stable disease lasting 3 months was reported in 27 patients, and stable disease lasting 6 months was reported in 21 patients.

Another phase II trial in metastatic RCC patients who hadn’t received previous treatment or who had failed RCC treatment on sunitinib and/or sorafenib demonstrated anti-tumoral activity with the combination of everolimus and bevacizumab. Bevacizumab was given at 10 mg/kg intravenously every 2 weeks and everolimus at 10 mg per day, orally. The median PFS in previously untreated patients was 9.1 months and 7.1 months in previously treated patients (35).

A placebo-controlled phase III trial was designed with everolimus as a second-line therapy for advanced clear cell carcinoma refractory to sunitinib, sorafenib, or both agents. 410 patients were randomized to receive everolimus or placebo. Patients were stratified according MSKCC (Memorial Sloan-Kettering Cancer Center) prognostics score and whether they had previously received one or two VEGF receptor tyrosine

---

Da Silva et al. Update on Targeted Therapy

kinase inhibitors. PFS was significantly prolonged for everolimus by 4.9 months when compared to 1.87 months with placebo (36). Common adverse effects reported were stomatitis, rash, diarrhea, and non-infectious pneumonitis. Everolimus was approved by the FDA in 2009 as an option for advanced RCC patients who had failed treatment with VEGF therapy. The usual dose is 10 mg once daily (37).

**Temsirolimus**

Temsirolimus is a specific inhibitor of mTOR and inhibits tumor angiogenesis by reducing synthesis of VEGF. Temsirolimus and IFN-α were used in a phase I/II Trial (38) for advanced RCC. 71 RCC patients were eligible and the recommended doses for temsirolimus was 15 mg and IFN-α was 6 million units. Among patients who received the recommended dose, 8% achieved partial response, 36% had a stable disease for 24 weeks, and the median overall progression-free survival was 9.1 months.

A phase III trial with 626 advanced and poor prognosis patients established that temsirolimus in combination with interferon did not improve survival (39). Overall survival medians in the interferon, temsirolimus, and combination groups were 7.3, 10.9, and 8.4 months, respectively. Monotherapy with temsirolimus showed longer overall survival and progression-free survival (P<0.001) than patients who received interferon alone (P<0.001). The median OS of temsirolimus and IFN-α as monotherapies were 10.9 and 7.3 months respectively. The median PFS time for the temsirolimus was 5.5 months compared with 3.1 months on IFN-α (P = 0.001).

Common adverse events were rash, peripheral edema, hyperglycemia, and hyperlipidemia in the temsirolimus group whereas asthenia was more significant in the interferon group. Grade 3 or 4 toxicity occurred in almost 90% of patients in the combination therapy. Temsirolimus was approved by the FDA in 2007 for advanced/metastatic RCC patients with three or more poor prognostic features. The standard dose is 25 mg IV/weekly.

**Non-clear cell histology**

Presently, there is a lack of phase III trials on systemic treatment of patients with non-clear cell RCC. Small studies for papillary type 1 and 2 were performed with sunitinib and everolimus, but none of them were prospectively randomized (40, 41). A phase II trial in patients with papillary RCC treated with foretinib (multikinase inhibitor) showed a median PFS of 9.3 months and 13% response rate. The presence of germ line MET mutation was a strong predictor of a response (42). There is a lack of data to support systemic therapy in patients with collecting-duct subtype. These tumors have been included in prospective trials but with smaller numbers of patients, invalidating any type of analysis (43).

**Cytoreductive Nephrectomy in target therapy era**

Cytoreductive nephrectomy has been shown to extend overall patient survival in the multimodal treatment of metastatic RCC comparing immunotherapy alone or combined with cytoreductive nephrectomy (44). In this target therapy era, it’s likely to remain part of the treatment and is recommended when possible. Complete removal of metastasis contributes to improved clinical prognosis and should be considered when feasible (2).

**Conclusion**

A better understanding of the tumor biology and the development and approval of multiple targeted agents for treatment of advanced RCC enables improved survival in patients with metastatic RCC. The standard of care in metastatic RCC is use of drugs that target VEGF and mTOR pathways. The third generation of tyrosine kinase inhibitors appears to have similar or superior efficacy as well as lower toxicity than existing agents.

Compared to previous systemic therapies, these drugs showed evident clinical benefits. They increase progression-free overall survival and improve the quality of life, but complete responses have been rarely noted. Some questions have yet to be answered and demand more debate. The
most efficacious sequence of therapies and time to start a second-line agent (before or not progression of the disease) should be addressed in further studies.

Acknowledgements: None

Conflict of Interest: None

References


Doi: http://dx.doi.org/10.1056/NEJMoa1303989

Doi: http://dx.doi.org/10.3389/fonc.2012.00013


Doi: http://dx.doi.org/10.1016/S1470-2045(07)70285-1

Doi: http://dx.doi.org/10.1016/S0140-6736(11)61613-9


Doi: http://dx.doi.org/10.1517/13543784.17.5.741

Doi: http://dx.doi.org/10.1007/s10637-013-9931-1

Doi: http://dx.doi.org/10.1016/j.ejca.2011.12.022

Doi: http://dx.doi.org/10.1200/JCO.2009.26.7849

Doi: http://dx.doi.org/10.1016/j.uroonc.2012.06.009


Doi: http://dx.doi.org/10.1056/NEJMoA066838

Doi: http://dx.doi.org/10.1093/annonc/mds582

Doi: http://dx.doi.org/10.1016/j.eururo.2012.06.043

Doi: http://dx.doi.org/10.1200/JCO.2012.43.383

Doi: http://dx.doi.org/10.1016/S1470-2045(09)70162-7

Doi: http://dx.doi.org/10.1097/01.ju.0000100110.610.61545.ae

Doi: http://dx.doi.org/10.1200/JCO.2013.50.3961